Halozyme Therapeutics Reports Q4 Earnings

Biopharmaceutical company posts revenue of $451.8 million, exceeding analyst estimates

Published on Feb. 19, 2026

Got story updates? Submit your updates here. ›

Halozyme Therapeutics Inc., a San Diego-based biopharmaceutical company, reported a loss of $141.6 million in its fourth quarter, missing Wall Street expectations. However, the company posted revenue of $451.8 million in the period, topping analyst forecasts.

Why it matters

Halozyme Therapeutics is a major player in the biopharmaceutical industry, and its quarterly earnings reports provide insight into the company's financial performance and outlook. The Q4 results, while showing a loss, indicate the company exceeded revenue expectations, which could be a positive sign for investors.

The details

On a per-share basis, Halozyme reported a loss of $1.20, while losses adjusted for one-time gains and costs were 24 cents per share. This missed the average estimate of $2.15 per share from four analysts surveyed by Zacks Investment Research. For the full year, the company reported a profit of $316.9 million, or $2.56 per share, and revenue of $1.4 billion.

  • Halozyme Therapeutics reported its Q4 earnings on Tuesday, February 17, 2026.

The players

Halozyme Therapeutics Inc.

A San Diego-based biopharmaceutical company that develops and commercializes novel oncology therapies.

Got photos? Submit your photos here. ›

What’s next

Halozyme Therapeutics expects full-year earnings in the range of $7.75 to $8.25 per share, with revenue in the range of $1.71 billion to $1.81 billion.

The takeaway

Halozyme Therapeutics' Q4 earnings report shows the company exceeded revenue expectations, but missed on earnings per share. The company's full-year outlook suggests continued growth, which could be of interest to investors in the biopharmaceutical sector.